Pharma & Biotech Global Week in Review 18 July 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

EWHC (Pat): Glatiramer acetate patent valid and infringed: Generics (t/a Mylan) v Yeda (IPKat) (PatLit) (The IP Factor)

Australia: Productivity Commission to review compulsory licensing regime under Patents Act 1990 (ipwars.com) (Patentology)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Australia: Productivity Commission to review compulsory licensing regime under Patents Act 1990 (ipwars.com) (Patentology)

Australia: IP Australia has lost perspective on ‘business method’ claims: APO decision in Celgene Corporation (Patentology)

Tanzania: Merck donates four minilabs to Tanzania FDA to boost control measures of counterfeit and sub-standard medicines (Afro-IP)

USPTO “clarifies” June 27, 2012 testimony on biologics exclusivity and India compulsory license (KEI)

USPTO and Congress bash India over Nexavar compulsory license (KEI) (Spicy IP)

US: BRCA gene case (Myriad) : James D. Watson, co-founder of double helix structure, rejects patentability of DNA and other amici filings (KEI) (Patent Docs)

US: Dr. Christopher Holman files amicus brief in Myriad case (Patent Docs)

US: Biopharmaceutical companies weigh-in on Myriad case (Patent Docs)

US: Health care professionals contend that isolated DNA and cDNA are patent ineligible (Patent Docs)

US: New USPTO guidance discusses patent-eligibility of inventions involving laws of nature (IP Spotlight) (Patents Post-Grant)

US: FDA approves class-wide opioid REMS after more than three years (FDA Law Blog)

 

Products

Aplenzin (Buproprion) – US: SD Florida denies Valeant’s motion for permanent injunction to prevent Watson from selling generic Aplenzin (Patent Docs)

Copaxone (Glatiramer acetate) – UK: EWHC (Pat): Glatiramer acetate patent valid and infringed: Generics (t/a Mylan) v Yeda (IPKat) (PatLit) (The IP Factor)

Cubicin (Daptomycin) – US: Cubist files patent infringement suit against Hospira in response to Para IV challenge (Patent Docs)

Formamet (Metformin) – US: CAFC accords presumption of validity to erroneously issued claims: Sciele Pharma v Lupin (Pharma Patents)

Gleevec (Imatinib) – India: Novartis’ patent law challenge postponed again (IP Watch)

K-Dur 20 (Potassium Chloride) – US: 3rd Circuit issues landmark decision in reverse payment case, setting up Supreme Court review: In Re: K-Dur Antitrust Litigation (Orange Book Blog)

Lidoderm (Lidocaine) – US: Endo Pharmaceuticals files patent infringement suit against TWi Pharmaceuticals in response to Para IV challenge (Patent Docs)

Linezolid – India: DHC issues ex-parte injunctions in favour of Symed Labs in Linezolid patent battle against Optimus and Sharon Bio-Medicine (Spicy IP)

Lipitor (Atorvastatin) – UK: EWHC (Pat) rejects application to make reference to the CJEU ahead of trial for preliminary ruling regarding the Pediatric Regulation: Dr Reddy’s v Pfizer (EPLAW) (IPKat)

 

 

%d bloggers like this: